Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Arthritis & Rheumatism

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ART.10885PMID 12687553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of rheumatoid nodules during anti–tumor necrosis factor α therapy with etanercept

  2002cited by this paper
• Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

  2002cited by this paper
• Etanercept in the treatment of adult patients with Still's disease.

  2002cited by this paper
• Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.

  2002cited by this paper
• Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis.

  2002cited by this paper
• Reactivation tuberculosis in a patient with anti–TNF-α treatment

  2001cited by this paper
• Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis.

  2001cited by this paper
• Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

  2001cited by this paper
• Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents

  2001cited by this paper
• Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.

  2001cited by this paper
• A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

  2001cited by this paper
• Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.

  2001cited by this paper
• Etanercept-induced subacute cutaneous lupus erythematosus.

  2001cited by this paper
• Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.

  2001cited by this paper
• Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.

  2001cited by this paper
• Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.

  2001cited by this paper
• The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).

  2001cited by this paper
• Use of infliximab in the treatment of Crohn's disease in children and adolescents.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis.

  2000cited by this paper
• Etanercept and urticaria in patients with juvenile idiopathic arthritis.

  2000cited by this paper
• Leukocytoclastic vasculitis due to etanercept.

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays.

  2000cited by this paper
• Leukocytoclastic vasculitis due to etanercept.

  2000cited by this paper
• Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

  2000cited by this paper
• Prognosis in juvenile arthritis.

  1999cited by this paper
• Prediction Equation for Glomerular Filtration Rate

  1999cited by this paper
• The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

  1998cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis.

  1995cited by this paper
• Factors associated with response to methotrexate in systemic‐onset juvenile chronic arthritis

  1994cited by this paper
• Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.

  1992cited by this paper
• Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype.

  1991cited by this paper
• Longitudinal data analysis for discrete and continuous outcomes.

  1986cited by this paper
• A double‐blind, placebo‐controlled trial

  1986cited by this paper
• Therapeutic criteria in rheumatoid arthritis.

  1949cited by this paper

• Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.

  2024cites this paper
• A patient with axial spondylarthritis who experienced pancytopenia while receiving anti-TNF therapy

  2024cites this paper
• Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

  2024cites this paper
• Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review

  2023cites this paper
• Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials

  2023cites this paper
• Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis

  2022cites this paper
• Updated clinical practice treat-to-target guidelines for JIA management: the Egyptian College of Pediatric Rheumatology initiative

  2022cites this paper
• Effect of vitamin D receptor gene polymorphism on lipid profile in Egyptian children with juvenile idiopathic arthritis

  2022cites this paper
• Systemic Juvenile Idiopathic Arthritis/Pediatric Still’s Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches

  2022cites this paper
• PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

  2021cites this paper
• Still’s Disease in the Constellation of Hyperinflammatory Syndromes: A Link with Kawasaki Disease?

  2021cites this paper
• Anterior Uveitis

  2021cites this paper
• Systemische Verlaufsform der juvenilen idiopathischen Arthritis (Morbus Still)

  2021cites this paper
• Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System

  2021cites this paper
• Current and emerging biologics for the treatment of juvenile idiopathic arthritis

  2020cites this paper
• Psychiatric Adverse Events Associated With Infliximab: A Cohort Study From the French Nationwide Discharge Abstract Database

  2020cites this paper
• Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study

  2020cites this paper
• Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry

  2020cites this paper
• Real-world effectiveness of biologic therapies in children and adults with juvenile idiopathic arthritis in the United Kingdom

  2019cites this paper
• Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions.

  2019cites this paper
• Systemic-Onset Juvenile Idiopathic Arthritis

  2019cites this paper
• Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method

  2019cites this paper
• Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.

  2019cites this paper
• Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than IBD

  2019cites this paper
• Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

  2019cites this paper
• The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis

  2019cites this paper
• Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis

  2019cites this paper
• İnsülin Benzeri Büyüme Faktörü-1 ve Premature Morbiditeleri: Bronkopulmoner Displazi, Premature Retinopatisi, İntraventriküler Kanama ve Nekrotizan Enterokolit

  2019cites this paper
• Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations

  2019cites this paper
• Efficacité et tolérance des agents biologiques dans les rhumatismes inflammatoires à début juvénile dans les essais cliniques randomisés et les études observationnelles

  2019cites this paper
• Evaluation of Patients with Systemic onset Juvenile Idiopathic Arthritis

  2019cites this paper
• Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease

  2019cites this paper
• Systemic Juvenile Idiopathic Arthritis

  2019cites this paper
• Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus

  2019cites this paper
• The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative.

  2018cites this paper
• Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

  2018cites this paper
• Management of Uveitis in Spondyloarthropathy: Current Trends.

  2018cites this paper
• Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting

  2018cites this paper
• Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis

  2018cites this paper
• Systemic Juvenile Idiopathic Arthritis.

  2018cites this paper
• Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis

  2018cites this paper
• Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges

  2018cites this paper
• Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis

  2018cites this paper
• S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis

  2018cites this paper
• Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

  2017cites this paper
• How I treat juvenile idiopathic arthritis: A state of the art review.

  2017cites this paper
• Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

  2017cites this paper
• Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review

  2017cites this paper
• Biologic Response Modifiers in Pediatric Rheumatology

  2017cites this paper
• Systemic-Onset Juvenile Idiopathic Arthritis

  2017cites this paper
• 121 – Neurologic Manifestations of Rheumatic Disorders of Childhood

  2017cites this paper
• Biologics in juvenile idiopathic arthritis: a narrative review

  2017cites this paper
• The lived experience of juvenile idiopathic arthritis in young people receiving etanercept

  2016cites this paper
• Stem cell autograft and allograft in autoimmune diseases

  2016cites this paper
• Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

  2016cites this paper
• [Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].

  2016cites this paper
• IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis

  2016cites this paper
• Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend

  2016cites this paper
• Chapter 13 – Pharmacology: Biologics

  2016cites this paper
• Management of Patients with Juvenile Idiopathic Arthritis

  2016cites this paper
• Chapter 16 – Systemic Juvenile Idiopathic Arthritis

  2016cites this paper
• Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.

  2016cites this paper
• Juvenile Idiopathic Arthritis: Diagnosis and Treatment

  2016cites this paper
• Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers

  2016cites this paper
• Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis

  2016cites this paper
• Hematopoietic stem cell transplantation for auto immune rheumatic diseases.

  2016cites this paper
• Considerations for special patient populations

  2016cites this paper
• Using a theragnostic approach in juvenile idiopathic arthritis

  2016cites this paper
• Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis

  2016cites this paper
• Canakinumab for the treatment of active systemic juvenile idiopathic arthritis

  2016cites this paper
• Cost‐Effectiveness Analysis of First‐Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis

  2016cites this paper
• Review of the latest systemic treatments for chronic non-infectious uveitis

  2016cites this paper
• Plasma levels of D-dimer in a 5-year-old girl with systemic juvenile idiopathic arthritis: A case report and literature review.

  2016cites this paper
• Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis.

  2016cites this paper
• Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

  2016cites this paper
• Tumor Necrosis Factor Inhibitors in Pediatric Rheumatology

  2016cites this paper
• Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice.

  2016cites this paper
• Biologic therapies in systemic juvenile idiopathic arthritis

  2016cites this paper
• Polyarticular Juvenile Idiopathic Arthritis

  2016cites this paper
• Современная фармакотерапия системного ювенильного артрита

  2015cites this paper
• Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database

  2015cites this paper
• Immunopathogenic and regulatory leukocyte subsets in juvenile idiopathic arthritis

  2015cites this paper
• Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years

  2015cites this paper
• Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent

  2015influential citation
• Arthrites juvéniles idiopathiques

  2015cites this paper
• Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations

  2015cites this paper
• APL-2, an altered peptide ligand derived from heat-shock protein 60, induces interleukin-10 in peripheral blood mononuclear cell derived from juvenile idiopathic arthritis patients and downregulates the inflammatory response in collagen-induced arthritis model

  2015cites this paper
• Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

  2015cites this paper
• The development and assessment of biological treatments for children.

  2015cites this paper
• Influence of biologic therapy on growth in children with chronic inflammatory connective tissue diseases

  2015cites this paper
• Susceptibility and prognostic factors in portuguese patients with juvenile idiopathic arthritis

  2015cites this paper
• Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

  2015cites this paper
• From bench to bedside and back again: translational research in autoinflammation

  2015cites this paper
• Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience

  2015cites this paper
• Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis.

  2015cites this paper
• ArtritisArtritis idiopáticas juveniles

  2015cites this paper
• Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics

  2015cites this paper
• Pharmacotherapy for uveitis: current management and emerging therapy

  2014cites this paper
• Rheumatologic Disorders in the PICU

  2014cites this paper
• Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis.

  2014cites this paper